SV

Street Verdict

Analyst Scorecard

A record of what Vikas Khemani said publicly, with the source. Not advice.

“Bullish on the pharma sector structurally, despite potential short-term adjustments for a quarter or two due to tariff announcements. He notes Indian companies primarily supply generic drugs, which the US cannot easily replace, and expects any tariff impact to be passed on to consumers, as the 200% tariff mentioned by Trump mainly targets innovator drugs, not generics.”
Nifty PharmaBullishCalled 01 Aug 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Vikas Khemani’s full track record